GSK's ICOS Agonist Disappointment Another Setback For Anticancer Ambitions
Feladilimab Phase II Combination Study With Keytruda Halted
Executive Summary
GlaxoSmithKline has discontinued treatment with its ICOS agonist feladilimab in the Phase II INDUCE-3 trial upon the recommendation of the study’s data monitoring committee, another setback for the big pharma’s plans to become a major force in the cancer therapy area.
You may also be interested in...
Sanofi Hits M&A Trail Again To Buy UK's KyMab
Another UK biotech has been swallowed up by a big pharma with Sanofi acquiring the Cambridge-based firm in a deal that could be worth almost $1.5bn.
Pipeline Watch: Phase III Readouts In Cervical Cancer, COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lundbeck's Migraine Therapy Vyepti: Overcoming The COVID-19 Effect
Denmark’s Lundbeck is aiming to build up use of its latest neurological, the long-acting migraine preventative, Vyepti, now that US healthcare is emerging from COVID-19-related restrictions, but is facing headwinds from loss of exclusivity on Northera.